Prognostic Significance of the Wnt Signalling Pathway Molecules APC, Beta-catenin and E-cadherin in Colorectal Cancer: a Tissue Microarray-based Analysis
Overview
Pathology
Affiliations
Aims: To investigate dysregulation of the wnt signalling pathway by assessing beta-catenin expression/increasing expression and loss of cytoplasmic adenomatous polyposis coli (APC) and membranous E-cadherin in colorectal cancer (CRC) and determining the prognostic significance of these variables.
Methods And Results: Unselected, non-consecutive CRC resections (n = 1420) were subdivided into three groups: mismatch repair (MMR)-proficient, MLH1- and presumed hereditary non-polyposis colonic cancer (HNPCC). Immunohistochemical analysis of beta-catenin expression (0% versus > 0%) and increasing expression (increasing percentage-positivity) and loss of APC and E-cadherin was performed using the tissue microarray technique. In MMR-proficient CRC, increased nuclear beta-catenin expression and loss of membranous E-cadherin were independently associated with higher N stage (P = 0.03 and < 0.0001), vascular invasion (P < 0.01 and < 0.001) and worse survival (P < 0.01 and < 0.001). Additionally, there was an association between loss of membranous E-cadherin and higher T stage (P = 0.03). In MLH1- CRC, loss of membranous E-cadherin was associated with higher N stage (P = 0.05) and worse survival (P = 0.03). In presumed HNPCC CRC nuclear beta-catenin and membranous E-cadherin were not associated with tumour progression or worse survival. In all CRC subsets loss of cytoplasmic APC was not associated with clinicopathological features.
Conclusions: Increasing nuclear beta-catenin expression and loss of membranous E-cadherin are independent, adverse prognostic factors in MMR-proficient and MLH1- CRC.
Chen H, Zhang J, Hao Q, Wu X, Guo J, Huang C Int J Colorectal Dis. 2024; 39(1):99.
PMID: 38926205 PMC: 11208236. DOI: 10.1007/s00384-024-04672-1.
Prime Editing and DNA Repair System: Balancing Efficiency with Safety.
Daliri K, Hescheler J, Pfannkuche K Cells. 2024; 13(10.
PMID: 38786078 PMC: 11120019. DOI: 10.3390/cells13100858.
Markowski A, Ustymowicz K, Markowska A, Romanczyk W, Guzinska-Ustymowicz K Cancers (Basel). 2023; 15(12).
PMID: 37370870 PMC: 10296849. DOI: 10.3390/cancers15123260.
Chang Y, Huang G, Chen Y, Huang K, Chen Y, Lin C BMC Cancer. 2023; 23(1):569.
PMID: 37340370 PMC: 10283306. DOI: 10.1186/s12885-023-10980-6.
Demarchi G, Perrone S, Esper Romero G, De Bonis C, Casasco J, Sevlever G Front Endocrinol (Lausanne). 2022; 13:870172.
PMID: 35928898 PMC: 9344046. DOI: 10.3389/fendo.2022.870172.